Gilead Sciences Inc Financials

GILD

Source SEC Filings (10-K/10-Q) Updated Dec 31, 2025 Currency USD FYE December

This page shows Gilead Sciences Inc (GILD) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 19 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Financial Health Signals

Financial Profile 73/100

Based on FY2025 annual data. Scores normalized against common benchmarks. How we calculate these scores

Profitability

Gilead Sciences Inc has an operating margin of 34.0%, meaning the company retains $34 of operating profit per $100 of revenue. This strong profitability earns a score of 98/100, reflecting efficient cost management and pricing power. This is up from 5.8% the prior year.

Growth

Gilead Sciences Inc's revenue grew a modest 2.4% year-over-year to $29.4B. This slow but positive growth earns a score of 37/100.

Leverage

Gilead Sciences Inc carries a low D/E ratio of 0.97, meaning only $0.97 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 82/100, indicating a strong balance sheet with room for future borrowing.

Liquidity

Gilead Sciences Inc's current ratio of 1.55 means current assets barely cover short-term liabilities. This tight liquidity results in a low score of 27/100, which could limit financial flexibility.

Cash Flow

100

Gilead Sciences Inc converts 32.1% of revenue into free cash flow ($9.5B). This strong cash generation earns a score of 100/100.

Returns

Gilead Sciences Inc earns a strong 37.5% return on equity (ROE), meaning it generates $37 of profit for every $100 of shareholders' equity. This efficient capital use earns a returns score of 94/100. This is up from 2.5% the prior year.

Altman Z-Score Safe

4.27

Gilead Sciences Inc scores 4.27, well above the 2.99 safe threshold. The score is driven primarily by a large market capitalization ($166.6B) relative to total liabilities ($36.3B). This indicates low bankruptcy risk based on profitability, leverage, and asset efficiency.

Piotroski F-Score Strong

8/9

Gilead Sciences Inc passes 8 of 9 financial strength tests. All 4 profitability signals pass (positive income, cash flow, and earnings quality), 2 of 3 leverage/liquidity signals pass, both operating efficiency signals pass.

Earnings Quality Cash-Backed

1.18x

For every $1 of reported earnings, Gilead Sciences Inc generates $1.18 in operating cash flow ($10.0B OCF vs $8.5B net income). This indicates profits are well-supported by actual cash generation, not accounting adjustments.

Interest Coverage Safe

9.8x

Gilead Sciences Inc earns $9.8 in operating income for every $1 of interest expense ($10.0B vs $1.0B). This wide margin provides strong safety for debt servicing, even if earnings decline temporarily.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

$29.4B

YoY+2.4%

5Y CAGR+3.6%

10Y CAGR-1.0%

Gilead Sciences Inc generated $29.4B in revenue in fiscal year 2025. This represents an increase of 2.4% from the prior year.

EBITDA

$12.8B

YoY+187.9%

5Y CAGR+18.1%

10Y CAGR-5.4%

Gilead Sciences Inc's EBITDA was $12.8B in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 187.9% from the prior year.

Net Income

$8.5B

YoY+1672.9%

5Y CAGR+133.3%

10Y CAGR-7.3%

Gilead Sciences Inc reported $8.5B in net income in fiscal year 2025. This represents an increase of 1672.9% from the prior year.

EPS (Diluted)

N/A

Cash & Balance Sheet

Free Cash Flow

$9.5B

YoY-8.2%

5Y CAGR+4.7%

10Y CAGR-7.4%

Gilead Sciences Inc generated $9.5B in free cash flow in fiscal year 2025, representing cash available after capex. This represents a decrease of 8.2% from the prior year.

Cash & Debt

$7.6B

YoY-24.3%

5Y CAGR+4.8%

10Y CAGR-5.2%

Gilead Sciences Inc held $7.6B in cash against $22.1B in long-term debt as of fiscal year 2025.

Dividends Per Share

$3.16

YoY+2.6%

5Y CAGR+3.0%

10Y CAGR+9.4%

Gilead Sciences Inc paid $3.16 per share in dividends in fiscal year 2025. This represents an increase of 2.6% from the prior year.

Shares Outstanding

1.24B

YoY-0.4%

5Y CAGR-0.2%

10Y CAGR-1.0%

Gilead Sciences Inc had 1.24B shares outstanding in fiscal year 2025. This represents a decrease of 0.4% from the prior year.

Margins & Returns

Gross Margin

78.8%

YoY+0.6pp

5Y CAGR-2.6pp

10Y CAGR-8.9pp

Gilead Sciences Inc's gross margin was 78.8% in fiscal year 2025, indicating the percentage of revenue retained after direct costs. This is up 0.6 percentage points from the prior year.

Operating Margin

34.0%

YoY+28.3pp

5Y CAGR+17.5pp

10Y CAGR-34.0pp

Gilead Sciences Inc's operating margin was 34.0% in fiscal year 2025, reflecting core business profitability. This is up 28.3 percentage points from the prior year.

Net Margin

28.9%

YoY+27.2pp

5Y CAGR+28.4pp

10Y CAGR-26.6pp

Gilead Sciences Inc's net profit margin was 28.9% in fiscal year 2025, showing the share of revenue converted to profit. This is up 27.2 percentage points from the prior year.

Return on Equity

37.5%

YoY+35.0pp

5Y CAGR+36.8pp

10Y CAGR-60.2pp

Gilead Sciences Inc's ROE was 37.5% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is up 35.0 percentage points from the prior year.

Capital Allocation

R&D Spending

$5.8B

YoY-1.8%

5Y CAGR+3.3%

10Y CAGR+6.8%

Gilead Sciences Inc invested $5.8B in research and development in fiscal year 2025. This represents a decrease of 1.8% from the prior year.

Share Buybacks

$1.9B

YoY+67.1%

5Y CAGR+4.0%

10Y CAGR-15.2%

Gilead Sciences Inc spent $1.9B on share buybacks in fiscal year 2025, returning capital to shareholders by reducing shares outstanding. This represents an increase of 67.1% from the prior year.

Capital Expenditures

$563.0M

YoY+7.6%

5Y CAGR-2.8%

10Y CAGR-2.8%

Gilead Sciences Inc invested $563.0M in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents an increase of 7.6% from the prior year.

GILD Income Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Revenue	$29.4B+2.4%	$28.8B+6.0%	$27.1B-0.6%	$27.3B-0.1%	$27.3B+10.6%	$24.7B
Cost of Revenue	$6.2B-0.3%	$6.3B-3.8%	$6.5B+14.9%	$5.7B-14.3%	$6.6B+44.4%	$4.6B
Gross Profit	$23.2B+3.1%	$22.5B+9.1%	$20.6B-4.7%	$21.6B+4.4%	$20.7B+2.9%	$20.1B
R&D Expenses	$5.8B-1.8%	$5.9B+3.3%	$5.7B+14.9%	$5.0B+8.2%	$4.6B-6.6%	$4.9B
SG&A Expenses	$5.8B-5.2%	$6.1B0.0%	$6.1B+7.4%	$5.7B+8.1%	$5.2B+1.8%	$5.2B
Operating Income	$10.0B+503.0%	$1.7B-78.1%	$7.6B+3.8%	$7.3B-26.1%	$9.9B+143.6%	$4.1B
Interest Expense	$1.0B+4.8%	$977.0M+3.5%	$944.0M+1.0%	$935.0M-6.6%	$1.0B+1.7%	$984.0M
Income Tax	$1.3B+509.5%	$211.0M-83.1%	$1.2B-0.1%	$1.2B-39.9%	$2.1B+31.5%	$1.6B
Net Income	$8.5B+1672.9%	$480.0M-91.5%	$5.7B+23.4%	$4.6B-26.2%	$6.2B+4961.0%	$123.0M
EPS (Diluted)	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24
Revenue	$7.9B+2.0%	$7.8B+9.7%	$7.1B+6.2%	$6.7B-11.9%	$7.6B+0.3%	$7.5B+8.5%	$7.0B+4.0%	$6.7B
Cost of Revenue	$1.6B+3.5%	$1.6B+4.5%	$1.5B-2.5%	$1.5B-2.6%	$1.6B+0.4%	$1.6B+1.9%	$1.5B-0.5%	$1.6B
Gross Profit	$6.3B+1.6%	$6.2B+11.1%	$5.6B+8.9%	$5.1B-14.4%	$6.0B+0.3%	$6.0B+10.4%	$5.4B+5.4%	$5.1B
R&D Expenses	$1.6B+17.6%	$1.3B-9.7%	$1.5B+8.1%	$1.4B-16.0%	$1.6B+17.6%	$1.4B+3.3%	$1.4B-11.1%	$1.5B
SG&A Expenses	$1.8B+32.2%	$1.4B-0.6%	$1.4B+8.5%	$1.3B-34.0%	$1.9B+33.0%	$1.4B+4.1%	$1.4B+0.1%	$1.4B
Operating Income	$2.0B-40.4%	$3.3B+34.5%	$2.5B+10.6%	$2.2B-8.8%	$2.5B+176.1%	$888.0M-66.4%	$2.6B+161.2%	-$4.3B
Interest Expense	$254.0M-0.8%	$256.0M+0.8%	$254.0M-2.3%	$260.0M+4.8%	$248.0M+4.2%	$238.0M+0.4%	$237.0M-6.7%	$254.0M
Income Tax	-$105.0M-117.8%	$589.0M+25.9%	$468.0M+40.1%	$334.0M-13.2%	$385.0M+229.6%	-$297.0M-167.8%	$438.0M+239.0%	-$315.0M
Net Income	$2.2B-28.5%	$3.1B+55.7%	$2.0B+49.0%	$1.3B-26.2%	$1.8B+42.3%	$1.3B-22.4%	$1.6B+138.7%	-$4.2B
EPS (Diluted)	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

GILD Balance Sheet

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Total Assets	$59.0B0.0%	$59.0B-5.0%	$62.1B-1.7%	$63.2B-7.0%	$68.0B-0.7%	$68.4B
Current Assets	$18.3B-4.3%	$19.2B+19.2%	$16.1B+11.4%	$14.4B-2.2%	$14.8B-7.7%	$16.0B
Cash & Equivalents	$7.6B-24.3%	$10.0B+64.2%	$6.1B+12.4%	$5.4B+1.4%	$5.3B-11.0%	$6.0B
Inventory	$1.8B+3.7%	$1.7B-4.3%	$1.8B+18.6%	$1.5B-6.9%	$1.6B-3.9%	$1.7B
Accounts Receivable	$4.9B+11.2%	$4.4B-5.2%	$4.7B-2.4%	$4.8B+6.3%	$4.5B-8.2%	$4.9B
Goodwill	$8.3B0.0%	$8.3B0.0%	$8.3B0.0%	$8.3B-0.2%	$8.3B+2.8%	$8.1B
Total Liabilities	$36.3B-8.4%	$39.7B+0.9%	$39.3B-6.3%	$41.9B-10.6%	$46.9B-6.6%	$50.2B
Current Liabilities	$11.8B-1.6%	$12.0B+6.4%	$11.3B+0.4%	$11.2B-3.2%	$11.6B+1.9%	$11.4B
Long-Term Debt	$22.1B-11.1%	$24.9B+7.4%	$23.2B+1.0%	$23.0B-8.8%	$25.2B-12.1%	$28.6B
Total Equity	$22.7B+17.4%	$19.3B-15.3%	$22.8B+7.5%	$21.2B+0.8%	$21.1B+15.8%	$18.2B
Retained Earnings	$13.7B+19.4%	$11.5B-29.5%	$16.3B+3.9%	$15.7B-3.9%	$16.3B+13.5%	$14.4B

Metric	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24
Total Assets	$59.0B+0.8%	$58.5B+5.0%	$55.7B-1.3%	$56.4B-4.3%	$59.0B+8.2%	$54.5B+1.8%	$53.6B-4.8%	$56.3B
Current Assets	$18.3B+2.6%	$17.9B+21.4%	$14.7B-12.9%	$16.9B-11.8%	$19.2B+29.7%	$14.8B+20.0%	$12.3B-12.3%	$14.0B
Cash & Equivalents	$7.6B+3.2%	$7.3B+42.5%	$5.1B-35.1%	$7.9B-20.7%	$10.0B+98.4%	$5.0B+81.7%	$2.8B-41.2%	$4.7B
Inventory	$1.8B-0.6%	$1.8B-2.2%	$1.8B+3.8%	$1.8B+2.9%	$1.7B-8.5%	$1.9B-7.7%	$2.0B+9.3%	$1.9B
Accounts Receivable	$4.9B-3.6%	$5.1B+6.6%	$4.8B+9.0%	$4.4B-0.7%	$4.4B-3.6%	$4.6B-1.6%	$4.7B-0.1%	$4.7B
Goodwill	$8.3B0.0%	$8.3B0.0%	$8.3B0.0%	$8.3B0.0%	$8.3B0.0%	$8.3B0.0%	$8.3B0.0%	$8.3B
Total Liabilities	$36.3B-1.8%	$37.0B+2.6%	$36.0B-3.3%	$37.3B-6.0%	$39.7B+10.0%	$36.0B+2.1%	$35.3B-8.9%	$38.8B
Current Liabilities	$11.8B-3.9%	$12.3B+9.9%	$11.2B-9.4%	$12.3B+2.8%	$12.0B+2.4%	$11.7B+8.8%	$10.8B-17.2%	$13.0B
Long-Term Debt	$22.1B0.0%	$22.1B0.0%	$22.1B0.0%	$22.1B-11.0%	$24.9B+16.1%	$21.4B-0.5%	$21.5B+0.1%	$21.5B
Total Equity	$22.7B+5.4%	$21.5B+9.5%	$19.7B+2.7%	$19.2B-0.9%	$19.3B+4.6%	$18.5B+1.1%	$18.3B+4.2%	$17.5B
Retained Earnings	$13.7B+7.1%	$12.8B+13.2%	$11.3B+3.6%	$10.9B-4.9%	$11.5B+3.8%	$11.1B-0.8%	$11.2B+4.8%	$10.7B

GILD Cash Flow Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Operating Cash Flow	$10.0B-7.5%	$10.8B+35.2%	$8.0B-11.8%	$9.1B-20.3%	$11.4B+39.4%	$8.2B
Capital Expenditures	$563.0M+7.6%	$523.0M-10.6%	$585.0M-19.6%	$728.0M+25.7%	$579.0M-10.9%	$650.0M
Free Cash Flow	$9.5B-8.2%	$10.3B+38.9%	$7.4B-11.1%	$8.3B-22.8%	$10.8B+43.7%	$7.5B
Investing Cash Flow	-$4.8B-39.0%	-$3.4B-52.3%	-$2.3B+8.2%	-$2.5B+21.2%	-$3.1B+78.6%	-$14.6B
Financing Cash Flow	-$7.7B-125.6%	-$3.4B+33.0%	-$5.1B+20.8%	-$6.5B+27.1%	-$8.9B-1252.9%	$770.0M
Dividends Paid	$4.0B+2.2%	$3.9B+2.9%	$3.8B+2.7%	$3.7B+2.9%	$3.6B+4.5%	$3.4B
Share Buybacks	$1.9B+67.1%	$1.1B+15.0%	$1.0B-28.4%	$1.4B+155.7%	$546.0M-65.5%	$1.6B

Metric	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24
Operating Cash Flow	$3.3B-19.0%	$4.1B+396.7%	$827.0M-52.9%	$1.8B-40.9%	$3.0B-31.0%	$4.3B+225.2%	$1.3B-40.3%	$2.2B
Capital Expenditures	$205.0M+39.5%	$147.0M+37.4%	$107.0M+2.9%	$104.0M-29.3%	$147.0M+4.3%	$141.0M+8.5%	$130.0M+23.8%	$105.0M
Free Cash Flow	$3.1B-21.2%	$4.0B+450.1%	$720.0M-56.4%	$1.7B-41.5%	$2.8B-32.1%	$4.2B+248.8%	$1.2B-43.5%	$2.1B
Investing Cash Flow	-$1.8B-329.7%	-$427.0M+79.8%	-$2.1B-409.9%	-$415.0M-84.4%	-$225.0M+68.3%	-$710.0M-131.3%	-$307.0M+86.1%	-$2.2B
Financing Cash Flow	-$1.3B+15.2%	-$1.5B+5.0%	-$1.6B+54.3%	-$3.4B-251.6%	$2.3B+263.9%	-$1.4B+53.3%	-$3.0B-117.0%	-$1.4B
Dividends Paid	$994.0M-0.1%	$995.0M-0.2%	$997.0M-1.3%	$1.0B+3.8%	$973.0M-0.4%	$977.0M-0.1%	$978.0M-1.2%	$990.0M
Share Buybacks	$230.0M-47.1%	$435.0M-17.5%	$527.0M-27.8%	$730.0M+108.6%	$350.0M+16.7%	$300.0M+200.0%	$100.0M-75.0%	$400.0M

GILD Financial Ratios

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Gross Margin	78.8%+0.6pp	78.3%+2.2pp	76.0%-3.2pp	79.3%+3.4pp	75.8%-5.7pp	81.5%
Operating Margin	34.0%+28.3pp	5.8%-22.3pp	28.1%+1.2pp	26.9%-9.5pp	36.3%+19.8pp	16.5%
Net Margin	28.9%+27.2pp	1.7%-19.2pp	20.9%+4.1pp	16.8%-6.0pp	22.8%+22.3pp	0.5%
Return on Equity	37.5%+35.0pp	2.5%-22.3pp	24.8%+3.2pp	21.6%-7.9pp	29.5%+28.9pp	0.7%
Return on Assets	14.4%+13.6pp	0.8%-8.3pp	9.1%+1.9pp	7.3%-1.9pp	9.2%+9.0pp	0.2%
Current Ratio	1.55-0.0	1.60+0.2	1.43+0.1	1.29+0.0	1.27-0.1	1.40
Debt-to-Equity	0.97-0.3	1.29+0.3	1.02-0.1	1.08-0.1	1.20-0.4	1.57
FCF Margin	32.1%-3.7pp	35.8%+8.5pp	27.4%-3.2pp	30.6%-9.0pp	39.6%+9.1pp	30.4%

Metric	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24
Gross Margin	79.5%-0.3pp	79.8%+1.0pp	78.8%+1.9pp	76.9%-2.2pp	79.1%-0.0pp	79.1%+1.3pp	77.8%+1.0pp	76.8%
Operating Margin	25.0%-17.8pp	42.8%+7.9pp	34.9%+1.4pp	33.6%+1.2pp	32.4%+20.6pp	11.8%-26.2pp	38.0%+102.7pp	-64.6%
Net Margin	27.6%-11.7pp	39.3%+11.6pp	27.7%+8.0pp	19.7%-3.8pp	23.6%+7.0pp	16.6%-6.6pp	23.2%+85.6pp	-62.4%
Return on Equity	9.6%-4.5pp	14.2%+4.2pp	10.0%+3.1pp	6.9%-2.4pp	9.2%+2.4pp	6.8%-2.1pp	8.8%+32.6pp	-23.8%
Return on Assets	3.7%-1.5pp	5.2%+1.7pp	3.5%+1.2pp	2.3%-0.7pp	3.0%+0.7pp	2.3%-0.7pp	3.0%+10.4pp	-7.4%
Current Ratio	1.55+0.1	1.45+0.1	1.32-0.1	1.37-0.2	1.60+0.3	1.26+0.1	1.14+0.1	1.08
Debt-to-Equity	0.97-0.1	1.03-0.1	1.13-0.0	1.16-0.1	1.29+0.1	1.16-0.0	1.18-0.0	1.23
FCF Margin	39.4%-11.6pp	51.0%+40.8pp	10.2%-14.6pp	24.8%-12.6pp	37.4%-17.9pp	55.2%+38.1pp	17.2%-14.4pp	31.6%

Similar Companies

Amgen Inc AMGN

$188.0B

Pfizer PFE

$153.8B

Sanofi FR SNY

$112.6B

Bristol-Myers Squibb Co BMY

$119.5B

GSK PLC GSK

$107.7B

Frequently Asked Questions

What is Gilead Sciences Inc's annual revenue?

Gilead Sciences Inc (GILD) reported $29.4B in total revenue for fiscal year 2025. This represents a 2.4% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is Gilead Sciences Inc's revenue growing?

Gilead Sciences Inc (GILD) revenue grew by 2.4% year-over-year, from $28.8B to $29.4B in fiscal year 2025.

Is Gilead Sciences Inc profitable?

Yes, Gilead Sciences Inc (GILD) reported a net income of $8.5B in fiscal year 2025, with a net profit margin of 28.9%.

What is Gilead Sciences Inc's EBITDA?

Gilead Sciences Inc (GILD) had EBITDA of $12.8B in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

How much debt does Gilead Sciences Inc have?

As of fiscal year 2025, Gilead Sciences Inc (GILD) had $7.6B in cash and equivalents against $22.1B in long-term debt.

What is Gilead Sciences Inc's gross margin?

Gilead Sciences Inc (GILD) had a gross margin of 78.8% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.

What is Gilead Sciences Inc's operating margin?

Gilead Sciences Inc (GILD) had an operating margin of 34.0% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.

What is Gilead Sciences Inc's net profit margin?

Gilead Sciences Inc (GILD) had a net profit margin of 28.9% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.

Does Gilead Sciences Inc pay dividends?

Yes, Gilead Sciences Inc (GILD) paid $3.16 per share in dividends during fiscal year 2025.

What is Gilead Sciences Inc's return on equity (ROE)?

Gilead Sciences Inc (GILD) has a return on equity of 37.5% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is Gilead Sciences Inc's free cash flow?

Gilead Sciences Inc (GILD) generated $9.5B in free cash flow during fiscal year 2025. This represents a -8.2% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is Gilead Sciences Inc's operating cash flow?

Gilead Sciences Inc (GILD) generated $10.0B in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

What are Gilead Sciences Inc's total assets?

Gilead Sciences Inc (GILD) had $59.0B in total assets as of fiscal year 2025, including both current and long-term assets.

What are Gilead Sciences Inc's capital expenditures?

Gilead Sciences Inc (GILD) invested $563.0M in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

How much does Gilead Sciences Inc spend on research and development?

Gilead Sciences Inc (GILD) invested $5.8B in research and development during fiscal year 2025.

Does Gilead Sciences Inc buy back shares?

Yes, Gilead Sciences Inc (GILD) spent $1.9B on share buybacks during fiscal year 2025, returning capital to shareholders by reducing shares outstanding.

How many shares does Gilead Sciences Inc have outstanding?

Gilead Sciences Inc (GILD) had 1.24B shares outstanding as of fiscal year 2025.

What is Gilead Sciences Inc's current ratio?

Gilead Sciences Inc (GILD) had a current ratio of 1.55 as of fiscal year 2025, which is generally considered healthy.

What is Gilead Sciences Inc's debt-to-equity ratio?

Gilead Sciences Inc (GILD) had a debt-to-equity ratio of 0.97 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Gilead Sciences Inc's return on assets (ROA)?

Gilead Sciences Inc (GILD) had a return on assets of 14.4% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is Gilead Sciences Inc's Altman Z-Score?

Gilead Sciences Inc (GILD) has an Altman Z-Score of 4.27, placing it in the Safe Zone (low bankruptcy risk). The Z-Score combines five financial ratios—working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets—to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.

What is Gilead Sciences Inc's Piotroski F-Score?

Gilead Sciences Inc (GILD) has a Piotroski F-Score of 8 out of 9, indicating strong financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Gilead Sciences Inc's earnings high quality?

Gilead Sciences Inc (GILD) has an earnings quality ratio of 1.18x, considered cash-backed (high quality). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Can Gilead Sciences Inc cover its interest payments?

Gilead Sciences Inc (GILD) has an interest coverage ratio of 9.8x, meaning it can comfortably cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.

How financially healthy is Gilead Sciences Inc?

Gilead Sciences Inc (GILD) scores 73 out of 100 on our Financial Profile, indicating strong overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.